Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00895375 · ClinicalTrials.gov registry record
Prevalence of Sleep Disturbances in Psoriasis
A clinical trial of Psoriasis, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 64
- Enrollment target
- 1
- Study location
NCT00895375: Completed study of Psoriasis, sponsored by Wake Forest University Health Sciences.
NCT00895375 is a study of Psoriasis that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 64 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00895375, a study of Psoriasis, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the sleep quality of patients with psoriasis to patients without psoriasis.
Conditions Studied
Study Locations (1)
North Carolina
- Wake Forest University Health Sciences, Dermatology - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2009-10 |
| Est. Completion | 2014-12 |
What the finished NCT00895375 record still lists
NCT00895375 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 0 interventions.
NCT00895375 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT00895375 about?
NCT00895375 is a clinical study titled "Prevalence of Sleep Disturbances in Psoriasis". The purpose of this study is to compare the sleep quality of patients with psoriasis to patients without psoriasis.
What is the current status of trial NCT00895375?
This trial is currently completed. The enrollment target is 64 participants. The study started on 2009-10. Estimated completion is 2014-12.
What conditions does trial NCT00895375 study?
This clinical trial studies the following conditions: Psoriasis.
Who is sponsoring clinical trial NCT00895375?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00895375 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00895375's enrollment target sits among peer trials
64 67th of 125 higher than 58 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet
RECRUITING · NA
-
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
RECRUITING
-
Duobrii in Combination With Biologics
RECRUITING · Phase 4
-
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia